NurExone Biologic Inc.
NRXBF
$0.40
$0.000.40%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.16% | -15.96% | -2.43% | 38.55% | 55.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.35% | -10.04% | 14.09% | 38.03% | 84.78% |
| Operating Income | -3.35% | 10.04% | -14.09% | -38.03% | -84.78% |
| Income Before Tax | -5.24% | 9.77% | -17.20% | -39.32% | -82.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.24% | 9.77% | -17.20% | -39.32% | -82.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.24% | 9.77% | -17.20% | -39.32% | -82.00% |
| EBIT | -3.35% | 10.04% | -14.09% | -38.03% | -84.78% |
| EBITDA | -2.66% | 10.94% | -12.00% | -36.19% | -83.09% |
| EPS Basic | 14.91% | 26.27% | 4.06% | -13.02% | -39.88% |
| Normalized Basic EPS | 14.79% | 26.47% | 4.07% | -12.59% | -39.22% |
| EPS Diluted | 14.91% | 26.27% | 4.06% | -13.02% | -39.88% |
| Normalized Diluted EPS | 14.79% | 26.47% | 4.07% | -12.59% | -39.22% |
| Average Basic Shares Outstanding | 23.67% | 22.80% | 22.13% | 23.66% | 30.21% |
| Average Diluted Shares Outstanding | 23.67% | 22.80% | 22.13% | 23.66% | 30.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |